<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04197986</url>
  </required_header>
  <id_info>
    <org_study_id>QBGJ398-302</org_study_id>
    <secondary_id>2019-003248-63</secondary_id>
    <nct_id>NCT04197986</nct_id>
  </id_info>
  <brief_title>Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations</brief_title>
  <official_title>Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>QED Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Helsinn Healthcare SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>QED Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study to evaluate&#xD;
      the efficacy of infigratinib (an oral targeted FGFR1-3 inhibitor) versus placebo, as adjuvant&#xD;
      treatment following surgery in adult subjects with invasive urothelial carcinoma and&#xD;
      susceptible FGFR3 genetic alterations (mutations, and gene fusions or rearrangements) who&#xD;
      have disease that is considered at high risk for recurrence with surgery alone. The study&#xD;
      enrolls subjects with either bladder cancer post radical cystectomy or upper tract urothelial&#xD;
      cancer post distal ureterectomy and/or nephrectomy. Study treatment is randomized 1:1 between&#xD;
      infigratinib or placebo with treatment up to 1 year or until invasive local, distal, or&#xD;
      metastatic disease recurrence confirmed by independent imaging reviewer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned (1:1) to receive oral infigratinib phosphate or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>As a double-blind study, participants, investigators, study monitor(s) and the clinical study team will be blinded to the treatment administered.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Centrally determine disease-free survival (DFS)</measure>
    <time_frame>Randomization through up to an approximated 5 years (60 months) after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare DFS including intraluminal low-risk recurrence</measure>
    <time_frame>Randomization through up to an approximated 5 years (60 months) after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare metastasis-free survival (MFS)</measure>
    <time_frame>Randomization through up to an approximated 5 years (60 months) after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare overall survival (OS)</measure>
    <time_frame>Randomization through 15 years after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare investigator-reviewed DFS</measure>
    <time_frame>Randomization through up to an approximated 5 years (60 months) after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and serious adverse events (SAEs) as a measure of safety and tolerability</measure>
    <time_frame>30-Day Post-Treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">218</enrollment>
  <condition>Upper Tract Urothelial Carcinomas</condition>
  <condition>Urothelial Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Infigratinib 125 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomly assigned (1:1) to receive oral infigratinib administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomly assigned (1:1) to receive oral placebo administered once daily for the first 3 weeks (21 days) of each 28-day cycle for a maximum of 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infigratinib</intervention_name>
    <description>Participants randomly assigned to infigratinib will receive hard gelatin capsules for oral administration of infigratinib 125 mg once a day (administered as one 100-mg capsule and one 25-mg capsule) using a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.</description>
    <arm_group_label>Infigratinib 125 mg</arm_group_label>
    <other_name>IP</other_name>
    <other_name>Study drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants randomly assigned to placebo will receive placebo matching in appearance the investigational product (infigratinib), which will be provided as hard gelatin capsules for oral use and will be administered once daily on a 3 weeks on (Days 1-21) /1 week off (Days 22-28) dosing schedule.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria&#xD;
&#xD;
          1. Are randomized within 120 days following nephroureterectomy, distal ureterectomy or&#xD;
             cystectomy.&#xD;
&#xD;
          2. Have histologically or cytologically confirmed, invasive urothelial carcinoma with&#xD;
             susceptible FGFR3 alterations. Variant histology is allowed provided urothelial&#xD;
             carcinoma is predominant (&gt;50%). Neuroendocrine (including small and large cell),&#xD;
             sarcomatoid, and plasmacytoid variants are excluded (any component).&#xD;
&#xD;
               1. Regarding samples and documentation of FGFR3&#xD;
&#xD;
                    -  i. FGFR3 mutation is confirmed if: FGFR3 gene is mutated in Exon 7 (R248C,&#xD;
                       S249C), Exon 10 (G370C, A391E, Y373C), or Exon 15 (K650M/T, K650E/Q)&#xD;
&#xD;
                  OR&#xD;
&#xD;
                    -  ii. FGFR3 gene fusion or FGFR3 rearrangement is confirmed based on the&#xD;
                       following genomic criteria if:&#xD;
&#xD;
                         -  Any fusion/rearrangement with a literature-derived known partner gene&#xD;
                            regardless of strand or frame.&#xD;
&#xD;
                         -  Fusion/rearrangements in the same strand that are in frame with a novel&#xD;
                            partner gene.&#xD;
&#xD;
                         -  Fusion/rearrangements with one breakpoint in the intron 17 - exon 18&#xD;
                            hotspot region and the other breakpoint in an intergenic region or&#xD;
                            another gene. This rule excludes 3' duplications comprising only exon&#xD;
                            18.&#xD;
&#xD;
                    -  iii. The amino acid numbers for the FGFR3 mutations refer to the functional&#xD;
                       FGFR3 isoform 1 (NP_000133.1) that is the NCBI Refseq ID used to report&#xD;
                       genetic alterations in FGFR3 by the FoundationOne® CDx test (F1CDx,&#xD;
                       Foundation Medicine, USA).&#xD;
&#xD;
                    -  iv. FGFR3 alteration must be confirmed by Foundation Medicine for F1CDx&#xD;
                       testing:&#xD;
&#xD;
                         -  The tumor sample to be used should be from the definitive surgical&#xD;
                            resection (cystectomy, nephroureterectomy, or distal ureterectomy), or&#xD;
                            from an archival biopsy of confirmed invasive urothelial carcinoma&#xD;
                            (≥pT2).&#xD;
&#xD;
               2. If status post neoadjuvant chemotherapy, pathologic stage at surgical resection&#xD;
                  must be Stage ≥ ypT2 and/or yN+. Prior neoadjuvant therapy is defined as at least&#xD;
                  3 cycles of neoadjuvant cisplatin-based chemotherapy with a planned cisplatin&#xD;
                  dose of 70 mg/m2/cycle. Subjects who received less than this or&#xD;
                  non-cisplatin-based neoadjuvant treatment are not excluded.&#xD;
&#xD;
               3. If not status post neoadjuvant chemotherapy, is ineligible to receive&#xD;
                  cisplatin-based adjuvant chemotherapy based on Galsky criteria:&#xD;
&#xD;
               4. Subjects who refuse cisplatin-based chemotherapy or who are ineligible to receive&#xD;
                  cisplatin-based chemotherapy based on Galsky criteria must also meet the&#xD;
                  following criteria:&#xD;
&#xD;
               5. Must have a centrally reviewed negative postoperative computed tomography (CT)&#xD;
                  (defined as lymph nodes with short axis &lt;1.0 cm and without growth and no distant&#xD;
                  metastases according to [RECIST v1.1 criteria or negative biopsy within 28 days&#xD;
                  before randomization to confirm absence of disease at baseline.&#xD;
&#xD;
          3. Have Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.&#xD;
&#xD;
          4. If a woman of childbearing potential, must have a negative pregnancy test within 7&#xD;
             days of the first dose of study drug. Sexually active males must use a condom during&#xD;
             intercourse while taking study drug and for 1 month after the last dose of study drug&#xD;
             and should not father a child during this period&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Presence of positive invasive surgical margins following nephroureterectomy, distal&#xD;
             ureterectomy, or cystectomy. In subjects not eligible for further surgery,&#xD;
             radiotherapy, or other efficacious treatment, microscopic positive noninvasive margins&#xD;
             (eg, carcinoma in situ) without gross residual disease are allowed.&#xD;
&#xD;
          2. Have received Bacillus Calmette-Guerin (BCG) or other intravesical therapy for&#xD;
             Non-Muscle Invasive Bladder Cancer (NMIBC) within the previous 30 days.&#xD;
&#xD;
          3. Are currently receiving or are planning to receive during participation in this study,&#xD;
             treatment with agents that are known moderate or strong inducers or inhibitors of&#xD;
             CYP3A4 and medications which increase serum phosphorus and/or calcium concentration.&#xD;
             Prior anticancer or other therapies are restricted as follows:&#xD;
&#xD;
               1. Prior adjuvant treatment for urothelial cancer is not allowed.&#xD;
&#xD;
               2. Prior neoadjuvant therapy (eg, chemotherapy, immunotherapy, or investigational)&#xD;
                  is allowed if inclusion criterion #4 is met. Prior neoadjuvant chemotherapy must&#xD;
                  have been completed within a period of time that is greater than the cycle length&#xD;
                  used for that treatment before first dose of study drug.&#xD;
&#xD;
               3. Prior biologic, immunotherapy, or investigational therapy should have been&#xD;
                  completed within a period that is ≥5 half-lives or 30 days, whichever is shorter,&#xD;
                  before the first dose of study drug.&#xD;
&#xD;
          4. Have previously or currently is receiving treatment with a mitogen-activated protein&#xD;
             kinase (MEK) or selective FGFR inhibitor.&#xD;
&#xD;
          5. Have a history of primary malignancy within the past 3 years other than (1) invasive&#xD;
             UBC or UTUC (ie, disease under study), (2) noninvasive urothelial carcinoma, (3) any&#xD;
             adequately treated in situ carcinoma or non-melanoma carcinoma of the skin, (4) any&#xD;
             other curatively treated malignancy that is not expected to require treatment for&#xD;
             recurrence during participation in the study, or (5) an untreated cancer on active&#xD;
             surveillance that may not affect the subject's survival status for ≥3 years based on&#xD;
             clinician assessment/statement and with medical monitor approval.&#xD;
&#xD;
          6. Have current evidence of corneal keratopathy or retinal disorder confirmed by&#xD;
             ophthalmic examination. Subjects with asymptomatic ophthalmic conditions assessed by&#xD;
             the investigator to pose minimal risk for study participation may be enrolled in the&#xD;
             study.&#xD;
&#xD;
          7. Have a history and/or current evidence of extensive tissue calcification&#xD;
&#xD;
          8. Have impaired gastrointestinal (GI) function or GI disease that may significantly&#xD;
             alter the absorption of oral infigratinib&#xD;
&#xD;
          9. Have current evidence of endocrine alterations of calcium/phosphate homeostasis (eg,&#xD;
             parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis),&#xD;
             unless well controlled.&#xD;
&#xD;
         10. Have consumed grapefruit, grapefruit juice, grapefruit hybrids, pomegranates, star&#xD;
             fruits, pomelos, or Seville oranges or products containing juice of these fruits&#xD;
             within 7 days before the first dose of study drug; have taken any Chinese herbal&#xD;
             medicine or Chinese patent medicine treatments with anticancer activity within 14 days&#xD;
             of the first dose of study drug.&#xD;
&#xD;
         11. Have insufficient bone marrow function:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt;1,000/mm3 (1.0 × 109/L).&#xD;
&#xD;
               2. Platelets &lt;75,000/mm3 (&lt;75 × 109/L).&#xD;
&#xD;
               3. Hemoglobin &lt;8.5 g/dL; transfusion support is allowed if &gt;1 week before&#xD;
                  randomization and hemoglobin remains stable.&#xD;
&#xD;
         12. Have insufficient hepatic and renal function:&#xD;
&#xD;
               1. Total bilirubin &gt;1.5 × upper limit of normal (ULN) of the testing laboratory (for&#xD;
                  subjects with documented Gilbert syndrome, direct bilirubin must be ≤1.5 × ULN&#xD;
                  and enrollment requires approval by the medical monitor).&#xD;
&#xD;
               2. AST/SGOT and ALT/SGPT &gt;2.5 × ULN of the testing laboratory.&#xD;
&#xD;
               3. Serum creatinine &gt;1.5 × ULN or a calculated or measured creatinine clearance of&#xD;
                  &lt;30 mL/min.&#xD;
&#xD;
         13. Have amylase or lipase &gt;2.0 × ULN.&#xD;
&#xD;
         14. Have abnormal calcium or phosphorus:&#xD;
&#xD;
               1. Inorganic phosphorus higher than 1.02 × ULN of the testing laboratory.&#xD;
&#xD;
               2. Total serum calcium (can be corrected) higher than 1.02 × ULN of the testing&#xD;
                  laboratory.&#xD;
&#xD;
         15. Have clinically significant cardiac disease including any of the following:&#xD;
&#xD;
               1. New York Heart Association (NYHA) Class ≥2B; subjects with known history or&#xD;
                  current symptoms of cardiac disease, or history of treatment with cardiotoxic&#xD;
                  agents, should have a clinical risk assessment of cardiac function using the NYHA&#xD;
                  classification.&#xD;
&#xD;
               2. Uncontrolled hypertension&#xD;
&#xD;
               3. Presence of CTCAE v5.0 Grade ≥2 ventricular arrhythmias, atrial fibrillation,&#xD;
                  bradycardia, or conduction abnormality.&#xD;
&#xD;
               4. Unstable angina pectoris or acute myocardial infarction ≤3 months before the&#xD;
                  first dose of study drug.&#xD;
&#xD;
               5. Average QTcF &gt;470 msec (males and females). Note: If the QTcF is &gt;470 msec in the&#xD;
                  first ECG, a total of 3 ECGs separated by ≥5 minutes should be performed. If the&#xD;
                  average of these 3 consecutive results for QTcF is ≤470 msec, the subject meets&#xD;
                  eligibility in this regard.&#xD;
&#xD;
               6. History of congenital long QT syndrome.&#xD;
&#xD;
         16. Have had a recent (≤3 months before the first dose of study drug) transient ischemic&#xD;
             attack or stroke.&#xD;
&#xD;
         17. If female, are pregnant or nursing (lactating).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corina Andresen, MD</last_name>
    <role>Study Director</role>
    <affiliation>QED Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>QED Therapeutics, Inc.</last_name>
    <phone>1-877-280-5655</phone>
    <email>Proof302.ct@qedtx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Kimbell</last_name>
      <phone>520-668-5678</phone>
      <email>stacey.kimbell@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sumanta Pal, M.D.</last_name>
      <phone>626-256-4673</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Kefauver</last_name>
      <phone>323-865-3000</phone>
      <email>daneshma@usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Center</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lawrence Karsh</last_name>
      <phone>303-433-4776</phone>
      <email>lkarsh@tucc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urological Research Network CORP</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel H Lopez</last_name>
      <phone>786-431-2014</phone>
      <email>isabel@besturology.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialist</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leslie Bellamy</last_name>
      <phone>850-696-4423</phone>
      <email>lbellamy@woodlandsmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaleena Jesson</last_name>
      <phone>404-778-5993</phone>
      <email>Kaleena.Kristine.Jesson@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UChicago Medicine Duchossois Center for Advanced Medicine (DCAM) - Hyde Park</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DuPage Medical Group - Warrenville Road</name>
      <address>
        <city>Lisle</city>
        <state>Illinois</state>
        <zip>60532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Shao</last_name>
      <phone>317-274-0972</phone>
      <email>dsshao@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane University/Southeastern Louisiana VA Health Care</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cara Rowe</last_name>
      <phone>504-988-0645</phone>
      <email>caraj@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guru Sonpavde</last_name>
      <phone>617-632-2429</phone>
      <email>gurup_sonpavde@dfci.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Louis University- SLUCare Academic Pavilion</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists - Midwest Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center at Cooper</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Logan</last_name>
      <phone>856-735-6396</phone>
      <email>logan-amanda@cooperhealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology - Saddle Brook</name>
      <address>
        <city>Saddle Brook</city>
        <state>New Jersey</state>
        <zip>07663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New Jersey Urology</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pilallis</last_name>
      <phone>856-673-1613</phone>
      <email>jpilallis@njurology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Romeo</last_name>
      <phone>518-262-8579</phone>
      <email>AMCUrologyResearch@amc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals - Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Arlington</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Smiddy</last_name>
      <phone>419-383-6962</phone>
      <email>Stephanie.smiddy@utoledo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug Hart</last_name>
      <phone>513-751-2273</phone>
      <email>douglas.hart@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Wisnieski</last_name>
      <phone>216-444-8311</phone>
      <email>guptas5@ccf.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University College of Medicine</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prisma Health Regional Urology</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urology Associates, P.C.</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxie Felton</last_name>
      <phone>615-250-9240</phone>
      <email>rcfelton@ua-pc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Houston Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital- Department of Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cinthya Yesenia Obando Perez Obando Perez, MD</last_name>
      <phone>346-238-6123</phone>
      <email>cobandoperez@houstonmethodist.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelly Maxfield</last_name>
      <phone>903-757-2122</phone>
      <email>shelly.maxfield@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UT Southwestern</name>
      <address>
        <city>Richardson</city>
        <state>Texas</state>
        <zip>75080</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurin Priddy</last_name>
      <phone>972-669-7044</phone>
      <email>laurin.priddy@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Jones</last_name>
      <phone>801-587-4385</phone>
      <email>alejandro.sanchez@hci.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates - Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gina Bright</last_name>
      <phone>757-466-8683</phone>
      <email>gina.bright@usoncology.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Liège - Sart Tilman</name>
      <address>
        <city>Liège</city>
        <state>Liège/Belgium</state>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amandine Catot</last_name>
      <phone>+ 32 4 366 76 64</phone>
      <email>pfreres@chuliege.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Netwerk Antwerpen Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <zip>202</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussel</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>BC Cancer- Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lyn Lorenzen</last_name>
      <phone>604.877.6000</phone>
      <email>Bernard.Eigl@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srikala Sridhar</last_name>
      <phone>416-946-4501</phone>
      <phone_ext>2520</phone_ext>
      <email>Srikala.Sridhar@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>McGill University Health Centre (MUHC)</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Leroux</last_name>
      <phone>514-934-1934</phone>
      <phone_ext>35161</phone_ext>
      <email>dianna.leroux@much.mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Québec Université Laval</name>
      <address>
        <city>Québec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Ile-de-France</state>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Nantes</city>
        <state>Nantes/France</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Paris</city>
        <state>Paris/France</state>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre de Lutte Contre le Cancer - Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <state>Rhone-Alpes</state>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <state>Strasbourg/France</state>
        <zip>67200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Anais</last_name>
      <phone>+33 3 68 76 7204</phone>
      <email>anais.robert@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <email>a.robert@icans.eu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <state>Toulouse/France</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Estelle Thiot</last_name>
      <phone>+33 5 31 15 58 70</phone>
      <email>thiot.estelle@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Villejuif</city>
        <state>Villejuif/France</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <state>Berlin/Germany</state>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf</name>
      <address>
        <city>Duesseldorf</city>
        <state>Nordrhein-Westfalen</state>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Urologicum Duisburg</name>
      <address>
        <city>Duisburg</city>
        <state>Nordrhein-WestFalen</state>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Kleinfeld</last_name>
      <phone>+49 203 500304-0</phone>
      <email>hellmis@urologicum-duisburg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Micaela Löbert</last_name>
      <phone>+49 201 723 3213</phone>
      <email>viktor.gruenwald@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne - Universitätsklinikum der Ruhr-Universität Bochum</name>
      <address>
        <city>Herne</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayleen Bartels</last_name>
      <phone>+49 2323 499 5252</phone>
      <email>florian.roghmann@elisabethgruppe.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Caritas-Krankenhaus St. Josef Klinik für Urologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathrin Hese</last_name>
      <phone>+49 941 782 3510</phone>
      <email>mschnabel@cartasstijosef.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beatrice Welte</last_name>
      <phone>+49 707 129 86 613</phone>
      <email>arnulf.stenzl@med.uni-tubingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale di Cremona</name>
      <address>
        <city>Cremona</city>
        <state>Cremona/Italy</state>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino</name>
      <address>
        <city>Genova</city>
        <state>Genova/Italy</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <state>Meldola/Italy</state>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Milano/Italy</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione G. Pascale</name>
      <address>
        <city>Napoli</city>
        <state>Naples</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <state>Pisa/italy</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro di Riferimento Oncologico di Basilicata</name>
      <address>
        <city>Rionero In Vulture</city>
        <state>Potenza</state>
        <zip>85028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Reggio Emilia/Italy</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università Campus Bio-Medico di Roma</name>
      <address>
        <city>Roma</city>
        <state>Roma/Italy</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria San Luigi Gonzaga</name>
      <address>
        <city>Orbassano</city>
        <state>Torino</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale di Trento - Presidio Ospedaliero Santa Chiara</name>
      <address>
        <city>Trento</city>
        <state>Trentino</state>
        <zip>38100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Universitaria Ospedaliera Consorziale - Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum Sittard-Geleen</name>
      <address>
        <city>Geleen</city>
        <state>Limburg</state>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Hospital</name>
      <address>
        <city>Nijmegen</city>
        <state>Nigmegen/Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roel Remij</last_name>
      <phone>+31 24-3658961</phone>
      <email>researchurologie@cwz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Médico de Puerto Rico</name>
      <address>
        <city>Rio Piedras</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>QED Investigative SIte</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Spain</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Spain</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Fernandez Saez</last_name>
      <phone>+34 932746085</phone>
      <email>rmorales@vhio.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>QED Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Spain</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona/Spain</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Badalona</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Taulí de Sabadell</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <state>Córdoba/Spain</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Girona</name>
      <address>
        <city>Girona</city>
        <state>Girona/Spain</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <state>Madrid/Spain</state>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>Madrid/Spain</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel G. Palos</last_name>
      <phone>+34 91 336 80 00</phone>
      <email>pgajate@oncologiahrc.com</email>
    </contact>
    <contact_backup>
      <phone>+34915183232</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <state>Madrid/Spain</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines de Cardenas</last_name>
      <phone>+34913303182</phone>
      <email>javier.puente@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Madrid/Spain</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Lucas</last_name>
      <phone>+34 914603310</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <state>Madrid/Spain</state>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susana Feliu</last_name>
      <phone>+34 91 727 70 50</phone>
      <email>alvaropintomarin@gmail.com</email>
    </contact>
    <contact_backup>
      <phone>+34 91 7277118</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <state>Madrid/Spain</state>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Morgades</last_name>
      <phone>+34917500193</phone>
      <email>esevillano@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <state>Sevilla/Spain</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina De Silva</last_name>
      <phone>+34954232992</phone>
      <email>bpvalderrama@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen De La Salud</name>
      <address>
        <city>Toledo</city>
        <state>Toledo/Spain</state>
        <zip>45005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto Valenciano de Oncologia</name>
      <address>
        <city>Valencia</city>
        <state>València</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tasmia Manir</last_name>
      <phone>0203.219.5200</phone>
      <email>Anna.Patikdou@hcahealthcare.co.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Puerto Rico</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 2, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGFR3 Genetic Alterations</keyword>
  <keyword>Upper Tract Urothelial Carcinomas</keyword>
  <keyword>UTUC</keyword>
  <keyword>Muscle Invasive Urothelial Carcinoma</keyword>
  <keyword>Fibroblast Growth Factor Receptor Inhibitor</keyword>
  <keyword>BGJ398</keyword>
  <keyword>FGFR3</keyword>
  <keyword>Urothelial Bladder Cancer</keyword>
  <keyword>UBC</keyword>
  <keyword>Infigratinib Phosphate</keyword>
  <keyword>Infigratinib</keyword>
  <keyword>Adjuvant</keyword>
  <keyword>Nephroureterectomy</keyword>
  <keyword>Distal ureterectomy</keyword>
  <keyword>Cystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infigratinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

